Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03204786 · ClinicalTrials.gov registry record · Phase 2
Intranasal Vasopressin Treatment in Children With Autism
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
NCT03204786: Completed Phase 2 study, sponsored by Stanford University.
NCT03204786 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 157 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03204786, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.
Interventions
- DRUG Placebo
- DRUG Vasopressin (USP) Injectable Solution [Vasostrict]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2024-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03204786
The ClinicalTrials.gov registry entry for NCT03204786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03204786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03204786 about?
NCT03204786 is a clinical study titled "Intranasal Vasopressin Treatment in Children With Autism". The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that admini...
What is the current status of trial NCT03204786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2018-02-20. Estimated completion is 2024-03-18.
What interventions are being tested in trial NCT03204786?
The interventions under investigation include: Placebo (DRUG), Vasopressin (USP) Injectable Solution [Vasostrict] (DRUG).
Who is sponsoring clinical trial NCT03204786?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.